PBYI
Price:
$3
Market Cap:
$147.26M
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limite...[Read more]
Industry
Biotechnology
IPO Date
2012-04-24
Stock Exchange
NASDAQ
Ticker
PBYI
According to Puma Biotechnology, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 166.37M. This represents a change of -22.20% compared to the average of 213.84M of the last 4 quarters.
The mean historical Enterprise Value of Puma Biotechnology, Inc. over the last ten years is 1.49B. The current 166.37M Enterprise Value has changed 1.02% with respect to the historical average. Over the past ten years (40 quarters), PBYI's Enterprise Value was at its highest in in the March 2015 quarter at 7.30B. The Enterprise Value was at its lowest in in the September 2024 quarter at 144.08M.
Average
1.49B
Median
628.66M
Minimum
177.08M
Maximum
5.64B
Discovering the peaks and valleys of Puma Biotechnology, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 339.91%
Maximum Annual Enterprise Value = 5.64B
Minimum Annual Increase = -77.60%
Minimum Annual Enterprise Value = 177.08M
Year | Enterprise Value | Change |
---|---|---|
2023 | 231.00M | 1.74% |
2022 | 227.05M | 28.22% |
2021 | 177.08M | -59.91% |
2020 | 441.70M | 10.58% |
2019 | 399.45M | -51.02% |
2018 | 815.61M | -77.60% |
2017 | 3.64B | 339.91% |
2016 | 827.66M | -66.72% |
2015 | 2.49B | -55.92% |
2014 | 5.64B | 92.69% |
The current Enterprise Value of Puma Biotechnology, Inc. (PBYI) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
211.71M
5-year avg
295.26M
10-year avg
1.49B
Puma Biotechnology, Inc.’s Enterprise Value is less than Ultragenyx Pharmaceutical Inc. (4.24B), less than Crinetics Pharmaceuticals, Inc. (4.93B), less than Arvinas, Inc. (1.69B), less than Revolution Medicines, Inc. (9.43B), less than Kura Oncology, Inc. (807.00M), less than 2seventy bio, Inc. (373.37M), less than Intercept Pharmaceuticals, Inc. (915.81M), less than Iovance Biotherapeutics, Inc. (2.52B), less than Sarepta Therapeutics, Inc. (12.11B), less than Madrigal Pharmaceuticals, Inc. (7.46B), less than Viking Therapeutics, Inc. (5.81B), greater than Hepion Pharmaceuticals, Inc. (5.35M), less than PTC Therapeutics, Inc. (3.21B), less than Heron Therapeutics, Inc. (315.25M), less than Coherus BioSciences, Inc. (259.52M), less than Larimar Therapeutics, Inc. (363.34M), greater than MacroGenics, Inc. (57.83M),
Company | Enterprise Value | Market cap |
---|---|---|
4.24B | $4.36B | |
4.93B | $5.20B | |
1.69B | $1.78B | |
9.43B | $9.55B | |
807.00M | $839.85M | |
373.37M | $185.91M | |
915.81M | $794.69M | |
2.52B | $2.61B | |
12.11B | $10.91B | |
7.46B | $7.58B | |
5.81B | $5.86B | |
5.35M | $4.62M | |
3.21B | $3.33B | |
315.25M | $162.74M | |
259.52M | $125.58M | |
363.34M | $393.05M | |
57.83M | $203.35M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Puma Biotechnology, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Puma Biotechnology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Puma Biotechnology, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Puma Biotechnology, Inc. (PBYI)?
What is the 3-year average Enterprise Value for Puma Biotechnology, Inc. (PBYI)?
What is the 5-year average Enterprise Value for Puma Biotechnology, Inc. (PBYI)?
How does the current Enterprise Value for Puma Biotechnology, Inc. (PBYI) compare to its historical average?